The challenges in the development of a prophylactic HIV-1 vaccine are unprecedented in the history of vaccinology. But there are reasons for optimism, and indeed, several promising vaccine concepts are currently moving toward clinical efficacy trials.
No takes yet. Share an insight, caveat, or question.
Dan H. Barouch (2013) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: